Blog Archive
-
▼
2008
(233)
-
▼
June
(29)
- KineMed and Daiichi Sankyo : New Discovery of Key ...
- Tranzyme Pharma to Present “Ghrelin Agonist (TZP-1...
- Speedel : SPP100 (TEKTURNA/RASILEZ) DEMONSTRATES P...
- Novo Nordisk and Sciele Pharma : FDA Approves Pran...
- SurModics : Initiation by Merck & Co., Inc. of Ph...
- OSI Pharmaceuticals : Diabetes/Obesity Preclinical...
- Osiris Therapeutics : $2 Million Milestone Payment...
- Melior : Option Agreement with Pfizer
- Nastech : Positive Intranasal Insulin Data at Amer...
- CytRx : Favorable Study Data with Iroxanadine in D...
- AVANIR : Grant of New Zenvia Patent
- Tethys Bioscience : Expanded Availability of PreDx...
- Antigen Express and Generex Biotechnology : Blood ...
- Roche : investigational diabetes drug, Taspoglutid...
- LCT : Diabetes Clinical Trial
- VeraLight Plans FDA Submission of Non-invasive Dia...
- VistaGen Licenses Customized Stem Cell-Based Drug ...
- Sanofi-aventis : Acomplia (rimonabant) significant...
- LifeScan and ResMed : Co-Marketing Agreement Focus...
- AstraZeneca & Bristol-Myers Squibb : ONGLYZA™ (s...
- MDS Pharma : Therapeutic Focus Metabolic Disorders
- Amylin Pharmaceuticals : Promising Data From Diabe...
- Novo Nordisk files for regulatory approval of lira...
- MacroChem : Presentation by Michael Zasloff, MD, P...
- Merck : New Data Released at Major Diabetes Meetin...
- Amylin, Lilly and Alkermes : Type 2 Diabetes Pat...
- Takeda : Voglibose (BASEN) for the prevention of t...
- Amylin and Lilly : Monotherapy BYETTA (exenatide) ...
- sanofi-aventis : Study Shows LANTUS Helped People ...
-
▼
June
(29)
Tuesday, June 10, 2008
MDS Pharma : Therapeutic Focus Metabolic Disorders
May 20, 2008 - MDS Pharma Services, a leading provider of innovative drug discovery and development solutions, has named two experienced medical professionals to lead its late stage clinical trial management activities related to respiratory ailments and metabolic disorders. Dr. Bernard Tisserand and Dr. Jonny L. Salyer have been named Executive Medical Directors for Respiratory Disorders and Metabolic Disorders, respectively. These therapeutic areas represent serious global public health concerns and are key areas of focus for MDS Pharma Services' customers. Respiratory disorders include conditions such as asthma, allergic rhinitis, chronic obstructive pulmonary disease (COPD), and community acquired pneumonia (CAP), while metabolic disorders include diabetes, dyslipidemia, obesity and metabolic syndrome, which is defined as a cluster of conditions that damage the cardiovascular system... MDS Pharma Services' Press Release -